Biomarker Analysis Services for Cystic Fibrosis
Protheragen offers specialized biomarker analysis services exclusively focused on supporting drug discovery and preclinical development for Cystic Fibrosis research. Our comprehensive biomarker panel is designed to advance the understanding of Cystic Fibrosis pathophysiology, providing pharmaceutical and biotech partners with actionable insights for therapeutic development. Please note that all services are strictly limited to research and preclinical drug development applications; we do not provide clinical diagnostic services.
Effective therapeutic intervention for Cystic Fibrosis begins with the robust discovery and identification of biomarkers that reflect disease mechanisms and progression. At Protheragen, our biomarker discovery services leverage advanced screening methodologies to identify molecular indicators associated with Cystic Fibrosis. Through systematic validation, we ensure that candidate biomarkers are relevant to disease biology and suitable for further development in drug discovery pipelines. Our approach encompasses literature mining, in silico prediction, and empirical screening in relevant preclinical models, followed by orthogonal validation to confirm biomarker specificity and utility.
Multi Omics: Our biomarker analysis services utilize an integrated multi-omics approach, encompassing genomics, transcriptomics, proteomics, and metabolomics to provide a holistic view of biological systems in Cystic Fibrosis. By applying cutting-edge -omics technologies, we enable the comprehensive identification of DNA, RNA, protein, and metabolite biomarkers. This approach facilitates the elucidation of key disease pathways, including ion channel dysfunction, inflammatory cascades, and tissue remodeling processes that are central to Cystic Fibrosis pathophysiology. Our multi-omics platforms allow for the discovery of novel biomarkers and the detailed characterization of molecular networks relevant to therapeutic targeting.
Candidate Validation: We employ rigorous candidate validation strategies to ensure that identified biomarkers are robustly associated with Cystic Fibrosis pathophysiology. Our validation process includes preliminary screening in relevant biological matrices, assessment of biomarker expression or activity in disease models, and evaluation of reproducibility across independent experiments. Criteria for prioritizing promising candidates include biological relevance, specificity to disease processes, detectability in accessible samples, and potential to inform therapeutic development. This systematic approach supports the selection of biomarkers with the greatest translational potential for preclinical drug development.
Diverse Technological Platforms: Protheragen offers custom assay development capabilities across a diverse range of technological platforms, including immunoassays, mass spectrometry, flow cytometry, molecular diagnostics, and histopathology/imaging. Our platforms are adaptable to specific research requirements, enabling tailored solutions for the quantification and characterization of biomarkers relevant to Cystic Fibrosis. Assay development is guided by the intended application, sample type, and analytical sensitivity required for preclinical studies.
Immunoassays: We develop and implement ELISA, chemiluminescent, and multiplex immunoassays for the quantitative measurement of protein biomarkers, such as cytokines and enzymes, in biological samples.
Mass Spectrometry: Our LC-MS/MS platforms enable high-sensitivity detection and quantification of proteins, peptides, and metabolites, supporting both targeted and discovery-based biomarker analyses.
Flow Cytometry: We utilize flow cytometry for cell-based biomarker detection, including surface and intracellular protein expression profiling in immune and epithelial cell populations.
Molecular Diagnostics: Nucleic acid-based assays, including qPCR and digital PCR, are employed for the detection and quantification of gene expression and genetic variants associated with Cystic Fibrosis.
Histopathology And Imaging: Advanced imaging and histological techniques are available for localization and semi-quantitative assessment of biomarkers in tissue sections, supporting spatial and contextual analysis.
Rigorous Method Validation: All analytical methods undergo rigorous validation according to established guidelines, including assessment of accuracy, precision, sensitivity, specificity, linearity, and reproducibility. Performance characteristics are thoroughly documented, and quality control measures are implemented throughout the workflow to ensure data reliability and integrity. Validation protocols are tailored to the intended research application and sample type, supporting robust and reproducible biomarker analysis in preclinical settings.
Our platforms support quantitative analysis of biomarker levels in a range of biological matrices, enabling precise measurement of molecular changes associated with Cystic Fibrosis. Quantitative data are generated using validated calibration standards and internal controls, facilitating comparative analyses across experimental groups and timepoints.
Sample Analysis: Protheragen processes a variety of sample types, including serum, plasma, sputum, bronchoalveolar lavage fluid, tissue extracts, and cell lysates. Each sample undergoes standardized preparation and analysis protocols, with stringent quality assurance procedures to minimize variability and ensure sample integrity. Our workflows are optimized for the preservation of biomarker stability and analytical accuracy throughout the process.
High Throughput Capabilities: We employ multiplexed analytical platforms and high-throughput workflows to enable the simultaneous measurement of multiple biomarkers within limited sample volumes. This approach increases analytical efficiency, conserves valuable preclinical samples, and supports large-scale screening studies. Automated systems and streamlined protocols further enhance throughput and reproducibility for biomarker discovery and validation projects.
| Gene Target | Biological Function | Application as a Biomarker |
|---|---|---|
| C-X-C motif chemokine ligand 8 (CXCL8) | C-X-C motif chemokine ligand 8 (CXCL8), also known as interleukin-8 (IL-8), is a chemokine produced by various cell types including macrophages, epithelial cells, and endothelial cells. Its primary biological function is to act as a chemoattractant, directing the migration of neutrophils to sites of infection or inflammation. CXCL8 exerts its effects by binding to specific G protein-coupled receptors (CXCR1 and CXCR2) on the surface of target cells, leading to activation and chemotaxis of neutrophils. In addition to its role in innate immune responses, CXCL8 can promote angiogenesis and modulate the activity of other immune cells, contributing to inflammatory processes. | CXCL8 has been studied as a biomarker in a variety of clinical contexts, particularly those involving inflammation and immune activation. Elevated levels of CXCL8 in biological fluids such as serum, plasma, or bronchoalveolar lavage fluid have been associated with inflammatory diseases, including infections, autoimmune disorders, and certain cancers. Measurement of CXCL8 concentrations has been used in research settings to assess the degree of inflammation, monitor disease progression, and evaluate response to therapy. |
| CF transmembrane conductance regulator (CFTR) | The cystic fibrosis transmembrane conductance regulator (CFTR) is a membrane-bound glycoprotein that functions primarily as a cAMP-regulated chloride channel in epithelial cells. It is a member of the ATP-binding cassette (ABC) transporter family and is involved in the regulation of salt and water transport across epithelial surfaces in organs such as the lungs, pancreas, intestines, and sweat glands. Proper CFTR activity maintains the hydration and viscosity of mucus and other secretions, contributing to normal respiratory, digestive, and reproductive function. Mutations in the CFTR gene disrupt chloride ion transport, leading to the pathophysiology of cystic fibrosis, characterized by thickened secretions and multi-organ dysfunction. | CFTR genetic analysis is widely used to detect pathogenic variants associated with cystic fibrosis. Identification of specific CFTR mutations can support diagnosis, carrier screening, and inform prognosis in affected individuals. Additionally, CFTR mutation status guides therapeutic decisions, particularly for targeted treatments that address specific functional defects in the CFTR protein. Beyond cystic fibrosis, CFTR testing may be applied in the evaluation of related conditions, such as congenital bilateral absence of the vas deferens (CBAVD) and some forms of pancreatitis. |
| S100 calcium binding protein A8 (S100A8) | S100 calcium binding protein A8 (S100A8), also known as myeloid-related protein 8 (MRP8), is a member of the S100 family of calcium-binding proteins. It is predominantly expressed in neutrophils and monocytes, where it forms a heterodimer with S100A9 (MRP14), known as calprotectin. S100A8 is involved in the regulation of inflammatory processes and immune responses. It participates in the modulation of leukocyte adhesion and migration, and acts as a pro-inflammatory mediator by interacting with pattern recognition receptors such as Toll-like receptor 4 (TLR4) and the receptor for advanced glycation end products (RAGE). S100A8 also has antimicrobial properties and contributes to the regulation of cytoskeletal dynamics within immune cells. | S100A8, often measured as part of the calprotectin complex with S100A9, is utilized as a biomarker of inflammation. Elevated levels of S100A8 are observed in various inflammatory and autoimmune conditions, including rheumatoid arthritis, inflammatory bowel disease, and systemic juvenile idiopathic arthritis. Its presence in biological fluids such as serum, plasma, and feces is used to monitor disease activity and assess the inflammatory state in clinical and research settings. |
| elastase, neutrophil expressed (ELANE) | ELANE encodes neutrophil elastase, a serine protease predominantly expressed in neutrophil granulocytes. Neutrophil elastase is stored in azurophilic granules and released during inflammation or infection. Its primary biological function is the degradation of various extracellular matrix proteins, such as elastin, collagen, and proteoglycans, as well as microbial proteins. This proteolytic activity facilitates neutrophil migration through tissues and contributes to the destruction of pathogens. ELANE activity is tightly regulated by endogenous inhibitors, including alpha-1 antitrypsin, to prevent excessive tissue damage. Mutations in ELANE are associated with congenital neutropenia syndromes, such as severe congenital neutropenia and cyclic neutropenia. | ELANE and its protein product, neutrophil elastase, have been utilized as biomarkers in several contexts. Elevated levels of neutrophil elastase in biological fluids (e.g., blood, bronchoalveolar lavage, sputum) are observed in inflammatory and infectious diseases, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and sepsis, reflecting neutrophil activation and degranulation. Measurement of ELANE gene mutations is applied in the diagnostic workup of congenital neutropenia syndromes. Additionally, neutrophil elastase activity is monitored to assess disease severity or progression in certain chronic inflammatory conditions. |
| insulin (INS) | Insulin (INS) is a peptide hormone produced by the beta cells of the pancreatic islets. Its primary biological function is the regulation of glucose homeostasis. Insulin facilitates cellular uptake of glucose, particularly in muscle and adipose tissue, by promoting the translocation of glucose transporter type 4 (GLUT4) to the cell surface. It also inhibits hepatic glucose production and stimulates glycogen synthesis in the liver and muscle. Additionally, insulin plays roles in lipid metabolism by promoting lipogenesis and inhibiting lipolysis, and in protein metabolism by enhancing protein synthesis and reducing proteolysis. | Insulin levels in blood are commonly measured to assess pancreatic beta cell function and insulin secretion. Quantification of circulating insulin is used in the evaluation of disorders such as diabetes mellitus, insulinoma, and metabolic syndrome. Measurement of insulin, often alongside glucose, aids in the assessment of insulin resistance, beta cell dysfunction, and in distinguishing between type 1 and type 2 diabetes. Insulin assays are also utilized in research and clinical settings to monitor the effects of therapeutic interventions targeting glucose metabolism. |
| interleukin 1 beta (IL1B) | Interleukin 1 beta (IL1B) is a pro-inflammatory cytokine produced primarily by activated macrophages, monocytes, and dendritic cells. It is synthesized as an inactive precursor (pro-IL1B) and is cleaved by caspase-1 to its active form. IL1B plays a central role in the regulation of immune and inflammatory responses. It promotes the expression of adhesion molecules on endothelial cells, induces fever by acting on the hypothalamus, stimulates the production of other cytokines, and contributes to the activation and recruitment of immune cells to sites of infection or injury. IL1B is also involved in the regulation of cell proliferation, differentiation, and apoptosis. | IL1B has been utilized as a biomarker for inflammation and immune activation. Elevated levels of IL1B in biological fluids, such as serum, plasma, or cerebrospinal fluid, have been associated with various inflammatory and autoimmune conditions, including rheumatoid arthritis, sepsis, and certain infectious diseases. Measurement of IL1B concentrations can provide information regarding the presence and extent of inflammatory processes and has been used in research and clinical studies to monitor disease activity and response to therapy. |
| interleukin 6 (IL6) | Interleukin 6 (IL6) is a multifunctional cytokine produced by a variety of cell types, including T cells, B cells, macrophages, fibroblasts, and endothelial cells. It plays a central role in the regulation of immune responses, acute-phase reactions, hematopoiesis, and inflammation. IL6 acts by binding to its receptor complex, which consists of the IL6 receptor (IL6R) and the signal-transducing component gp130, leading to activation of the JAK/STAT signaling pathway. This cytokine stimulates the production of acute-phase proteins in the liver, promotes the differentiation of B cells into antibody-producing cells, influences T cell differentiation, and modulates the balance between pro-inflammatory and anti-inflammatory activities in the immune system. | IL6 is measured in various biological fluids, such as serum or plasma, as an indicator of inflammation or immune activation. It is commonly used as a biomarker to assess the presence and severity of inflammatory conditions, including infections, autoimmune diseases, and certain cancers. Elevated IL6 levels have been observed in disorders such as rheumatoid arthritis, sepsis, and COVID-19, correlating with disease activity or severity in some contexts. Measurement of IL6 can aid in monitoring disease progression, evaluating response to therapy, and supporting clinical decision-making in inflammatory and immune-mediated diseases. |
| matrix metallopeptidase 9 (MMP9) | Matrix metallopeptidase 9 (MMP9) is a member of the matrix metalloproteinase family, which consists of zinc-dependent endopeptidases involved in the degradation of extracellular matrix (ECM) components. MMP9 specifically cleaves type IV and V collagens, elastin, and gelatin, playing a significant role in tissue remodeling, wound healing, and angiogenesis. It is produced by various cell types, including neutrophils, macrophages, and epithelial cells, and its activity is tightly regulated at multiple levels, including gene expression, zymogen activation, and inhibition by tissue inhibitors of metalloproteinases (TIMPs). MMP9 is also implicated in processes such as leukocyte migration, inflammation, and the breakdown of physical barriers during pathological conditions. | MMP9 has been studied as a biomarker in several contexts due to its involvement in ECM remodeling and inflammation. Elevated levels of MMP9 in biological fluids such as serum, plasma, or tissue have been associated with various pathological conditions, including cancer, cardiovascular diseases, and inflammatory disorders. In oncology, increased MMP9 expression has been observed in tumor tissues and is often correlated with tumor invasion and metastasis. In cardiovascular research, higher MMP9 concentrations have been detected in patients with acute coronary syndromes and atherosclerosis. Additionally, MMP9 has been investigated as a marker of disease activity and tissue injury in conditions such as chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, and neurological disorders. |
| myeloperoxidase (MPO) | Myeloperoxidase (MPO) is a heme-containing peroxidase enzyme predominantly expressed in neutrophil granulocytes and, to a lesser extent, in monocytes. It is stored in the azurophilic granules of these cells and released during degranulation. MPO catalyzes the conversion of hydrogen peroxide and chloride ions into hypochlorous acid (HOCl), a potent antimicrobial agent that contributes to the destruction of pathogens during the innate immune response. In addition to its microbicidal activity, MPO and its reactive products can modify host tissues and biomolecules, thereby contributing to inflammatory processes and oxidative tissue damage. | MPO has been studied as a biomarker of inflammation and oxidative stress. Elevated MPO levels have been observed in various conditions characterized by neutrophil activation, including cardiovascular diseases, such as acute coronary syndromes, heart failure, and atherosclerosis, as well as certain autoimmune and inflammatory disorders. Measurement of MPO concentrations in blood, plasma, or tissue samples has been used in research to assess disease activity, risk stratification, and the extent of inflammatory response. |
| tumor necrosis factor (TNF) | Tumor necrosis factor (TNF) is a pro-inflammatory cytokine primarily produced by activated macrophages, as well as by a variety of other cell types including lymphocytes, natural killer cells, and endothelial cells. TNF plays a central role in mediating inflammation and immune responses. It exerts its effects by binding to two distinct receptors, TNFR1 and TNFR2, leading to the activation of signaling pathways such as NF-κB and MAPKs. These pathways regulate the expression of genes involved in inflammation, cell proliferation, differentiation, and apoptosis. TNF is a key mediator in the pathogenesis of several inflammatory and autoimmune diseases, and it also contributes to host defense mechanisms against infections and tumor cells. | TNF levels in blood, tissues, or other biological fluids are commonly measured as an indicator of inflammatory activity. Elevated TNF concentrations have been associated with a variety of conditions, including rheumatoid arthritis, inflammatory bowel disease, sepsis, and certain cancers. In clinical and research settings, TNF is used to monitor disease activity, evaluate the response to anti-TNF therapies, and investigate the pathophysiology of inflammatory diseases. |
Explore Research Opportunities with Protheragen. Our biomarker research services offer advanced capabilities for the exploratory identification, characterization, and quantification of molecular indicators relevant to Cystic Fibrosis in preclinical drug development. All biomarkers discussed are research targets only and are not claimed as validated or mandatory for any application. We emphasize the exploratory and research-focused nature of our work, supporting partners from early discovery through preclinical stages. Protheragen maintains scientific objectivity and does not endorse any biomarker as required or definitive for Cystic Fibrosis research.
We invite you to connect with Protheragen to discuss collaborative opportunities in exploratory biomarker research for Cystic Fibrosis. Our team is dedicated to scientific exchange and collaborative discovery, supporting knowledge-driven advancement in preclinical therapeutic development.
Make Order
Experimental Scheme
Implementation
Conclusion
